© 2004 by European Society of Cardiology
Copyright © 2004, European Society of Cardiology
Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice
aINSERM U582, Institut de Myologie, Bâtiment Babinski, GH Pitié-Salpêtrière, 47 boulevard de l'Hôpital, 75651 Paris, France
bINSERM IFR14, GH Salpêtrière, Paris, France
cInstitute of Experimental and Clinical Pharmacology, University Hospital Eppendorf, Hamburg, Germany
dInstitute of Molecular Medicine, UCSD, La Jolla, CA, USA
eService de Cardiologie, GH Pitié-Salpêtrière, Paris, France
* Corresponding author. INSERM U582, Institut de Myologie, Bâtiment Babinski, GH Pitié-Salpêtrière, 47 boulevard de l'Hôpital, 75651 Paris, France. Tel.: +33-1-4216-5715; fax: +33-1-4216-5700. Email address: l.carrier{at}myologie.chups.jussieu.fr
Objective: Cardiac myosin-binding protein C (cMyBP-C) gene mutations are involved in familial hypertrophic cardiomyopathy (FHC). Many of these mutations produce truncated proteins, which are unstable in the cardiac tissue of patients, suggesting that haploinsufficiency could account for the development of the phenotype. However, existing mouse models of cMyBP-C gene mutations have represented hypomorphic alleles without evidence of asymmetric septal hypertrophy, a key FHC phenotypic feature. In the present study, we generated a new model of cMyBP-C null mice and characterized the phenotype in both homozygotes and heterozygotes at different ages. Methods: The mouse model was based upon the targeted deletion of exons 1 and 2, which contain the transcription initiation site, and the phenotype was determined by molecular, functional and morphological analyses. Results: Herein, we demonstrate that inactivation of one or two mouse cMyBP-C alleles leads to different cardiac disorders at different post-natal time windows. The homozygous cMyBP-C null mice do not express the cMyBP-C gene, develop eccentric left ventricular hypertrophy with decreased fractional shortening at 3–4 months of age and a markedly impaired relaxation after 9 months. This is associated with myocardial disarray and an increase of interstitial fibrosis. The heterozygous cMyBP-C null mice present a slight but significant decrease of cMyBP-C amount and develop asymmetric septal hypertrophy associated with fibrosis at 10–11 months of age. Conclusion: These data provide evidence that heterozygous cMyBP-C null mice represent the first model with a key feature of human FHC that is asymmetric septal hypertrophy.
KEYWORDS Sarcomere; Targeted transgenesis; Cardiomyopathy; Hypertrophy
1 Contributed equally to the work.
Time for primary review 27 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. J. van Dijk, D. Dooijes, C. dos Remedios, M. Michels, J. M.J. Lamers, S. Winegrad, S. Schlossarek, L. Carrier, F. J. ten Cate, G. J.M. Stienen, et al. Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy: Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction Circulation, March 24, 2009; 119(11): 1473 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF]
|
|